Can't find Besremi? Learn about alternative treatments for polycythemia vera, including Hydroxyurea, Jakafi, and other options your doctor may consider.
Dealing with polycythemia vera is stressful enough without the added worry of not being able to fill your prescription. If you've been prescribed Besremi (Ropeginterferon Alfa-2b-njft) but can't get it due to supply issues, insurance delays, or cost concerns, there are other treatment options worth discussing with your hematologist.
This guide covers what Besremi does, how it works, and the most common alternatives that your doctor may recommend if Besremi isn't available.
Besremi is a pegylated interferon therapy manufactured by PharmaEssentia Corporation. It was FDA-approved in 2021 for the treatment of polycythemia vera (PV) in adults — making it the first and only interferon therapy with a specific FDA indication for PV.
Polycythemia vera is a type of blood cancer (myeloproliferative neoplasm) where the bone marrow produces too many red blood cells. Left untreated, PV can lead to blood clots, stroke, heart attack, and progression to more serious conditions like myelofibrosis or acute leukemia.
For a full overview of this medication, read our article on what Besremi is, its uses, and dosage information.
Besremi works differently from most PV treatments. It's an immunotherapy — not chemotherapy — that binds to the interferon alpha/beta receptor on cell surfaces. This activates the JAK-STAT signaling pathway, which triggers the immune system to target and reduce the JAK2 V617F mutant clone, the genetic mutation driving PV in most patients.
Over time, Besremi can reduce the mutant clone burden, potentially altering the course of the disease rather than just managing blood counts. It's given as a subcutaneous injection every two weeks, with doses ranging from 50 mcg to 500 mcg.
For more on how it works, see our detailed explainer on Besremi's mechanism of action.
There are several reasons you might need to consider alternatives to Besremi:
What it is: Hydroxyurea is an oral antimetabolite medication and the most widely used first-line cytoreductive therapy for polycythemia vera. It's been used for decades and is considered the standard of care.
How it works: Hydroxyurea reduces blood cell production by interfering with DNA synthesis in the bone marrow. It effectively lowers red blood cell, white blood cell, and platelet counts.
Key details:
Best for: Patients who need immediate cytoreduction, those who can't tolerate interferons, or those whose insurance requires step therapy before approving Besremi.
What it is: Jakafi is an oral JAK1/JAK2 inhibitor manufactured by Incyte. It's FDA-approved for PV patients who have had an inadequate response to or cannot tolerate Hydroxyurea.
How it works: Ruxolitinib blocks the JAK1 and JAK2 signaling pathways that drive the overproduction of blood cells in PV. It's particularly effective at controlling symptoms like itching, night sweats, and fatigue, and can reduce spleen size.
Key details:
Best for: Patients who have already tried Hydroxyurea and need a second-line option, or those with significant symptom burden (itching, fatigue, enlarged spleen).
What it is: Pegasys is another pegylated interferon that has been used off-label for polycythemia vera for many years. It's not FDA-approved specifically for PV but is included in NCCN treatment guidelines.
How it works: Like Besremi, Pegasys activates the interferon signaling pathway and can reduce the JAK2 mutant clone burden. It's given as a weekly subcutaneous injection.
Key details:
Best for: Patients who were already stable on Pegasys and can still access it, though many are being transitioned to Besremi.
What it is: Anagrelide is an oral medication primarily used to reduce platelet counts. While it's mainly indicated for essential thrombocythemia, it's sometimes used in PV patients with very high platelet counts.
How it works: It reduces platelet production by inhibiting megakaryocyte maturation in the bone marrow.
Key details:
Best for: PV patients with particularly high platelet counts who need additional platelet control alongside other treatments.
Regardless of which medication you're taking, therapeutic phlebotomy (blood removal) remains a cornerstone of PV management. Your doctor may increase the frequency of phlebotomy sessions if you're between medications or waiting for a new treatment to take effect. Phlebotomy quickly reduces your hematocrit (the percentage of red blood cells in your blood) and lowers the immediate risk of blood clots.
Choosing a Besremi alternative is a conversation between you and your hematologist. Here are some questions to ask:
For information on Besremi's side effects to compare with alternatives, check out our article on Besremi side effects and when to call your doctor.
Not being able to fill your Besremi prescription is frustrating, but it doesn't mean you're out of options. Hydroxyurea, Jakafi, and even phlebotomy can help manage your polycythemia vera while you work on getting back to Besremi. The most important thing is to stay in close contact with your hematologist and never stop treatment without medical guidance.
If you're still trying to find Besremi, use Medfinder to search specialty pharmacies, or read our guide on how to find Besremi in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
